Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism

Journal of Endocrinological Investigation

Volumn 31, Issue 8, 2008, Pages 718-723

  Minnemann, T ^a   Schubert, M ^a   Freude, S ^a   Hubler D ^b   Gouni Berthold, I ^a   Schumann, C ^a   Christoph, A ^a   Oettel, M ^b   Ernst, M ^b   Mellinger, U ^b   Krone, W ^a   Jockenhovel F ^c,d  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b BAYER PHARMA AG   (Germany)

^c Christian Hospital Herne   (Germany)

^d Evangelisches Krankenhaus Herne   (Germany)

Author keywords

Efficacy; Pharmacokinetics; Safety; Testosterone enanthate; Testosterone undecanoate

Indexed keywords

HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LONG ACTING DRUG; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; TESTOSTERONE ENANTATE; TESTOSTERONE UNDECANOATE; TRIACYLGLYCEROL;

ACNE; ADULT; ANDROGEN THERAPY; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVULSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GRIP STRENGTH; HAIR LOSS; HEMATOCRIT; HEMATOMA; HUMAN; HYPOGONADISM; INJECTION SITE PAIN; LONG TERM CARE; MALE; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SNORING; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 56249092109     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03346421     Document Type: Article

References (23)

1. Gooren LJ, Bunck MC. Androgen replacement therapy: present and future. Drugs 2004, 64: 1861-91.
2. Kaufman JM, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005, 26: 833-76.
3. Nieschlag E, Behre HM, Bouchard P, et al. Testosterone replacement therapy: current trends and future directions. Hum Reprod Update 2004, 10: 409-19.
4. Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006, 65: 275-81.
5. Behre HM, Wang C, Handelsman DJ, Nieschlag E. Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM, editors. Testosterone, Action, Deficiency, Substitution. Cambridge: Cambridge University Press. 2004, 405-44.
6. Schubert M, Minnemann T, Hübler D, et al. Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 2004, 89: 5429-34.
7. Harle L, Basaria S, Dobs AS. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism. Expert Opin Pharmacother 2005, 6: 1751-9.
8. Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E. Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I studies. Eur J Endocrinol 1999, 140: 414-9.
9. Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006, 154: 899-906.
10. Rebuffe-Scrive M, Mårin P, Björntorp P. Effect of testosterone on abdominal adipose tissue in men. Int J Obes 1991, 15: 791-5.
11. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: implications for testosterone therapy. J Urol 2005, 174: 827-34.
12. Jockenhövel F, Blum WF, Vogel E, et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 1997, 82: 2510-3.
13. Blum WF, Englaro P, Hanitsch S, et al. Plasma leptin levels in healthy children and adolescents: dependence on body mass index, body fat mass, gender, pubertal stage, and testosterone. J Clin Endocrinol Metab 1997, 82: 2904-10.
14. Elbers JM, Asscheman H, Seidell JC, Frölich M, Meinders AE, Gooren LJ. Reversal of the sex difference in serum leptin levels upon cross-sex hormone administration in transsexuals. J Clin Endocrinol Metab 1997, 82: 3267-70.
15. Liu PY, Death AK, Handelsman DJ. Androgens and cardiovascular disease. Endocr Rev 2003, 24: 313-40.
16. Whitsel EA, Boyko EJ, Matsumoto AM, Anawalt BD, Siscovick DS. Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis. Am J Med 2001, 111: 261-9.
17. Wu FC, von Eckardstein A. Androgens and coronary artery disease. Endocr Rev 2003, 24: 183-217.
18. Morley JE, Perry HM 3rd, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993, 41: 149-52.
19. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82: 1661-7.
20. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000, 85: 2670-7.
21. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004, 89: 2085-98.
22. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab 1992, 75: 1092-8.
23. Jockenhövel F, Vogel E, Reinhardt W, Reinwein D. Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 1997, 2: 293-8.